Cargando…

Postoperative radiotherapy for the young–old patients with thoracic esophageal squamous cell carcinoma: A 2-center experience

This study aimed to retrospectively analyze the efficacy and safety of esophagectomy and postoperative radiotherapy (PORT) for patients with thoracic esophageal squamous cell carcinoma (TESCC) in the young–old (aged between 65 and 75 years). The clinical data of 166 young–old patients with esophagea...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Wei, Yang, Min, Jiang, Wanrong, Ge, Xiaolin, Sun, Xiangdong, Zhou, Bin, Liu, Feng, Jiang, Kai, Shen, Fangcheng, Sun, Xinchen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220665/
https://www.ncbi.nlm.nih.gov/pubmed/32332598
http://dx.doi.org/10.1097/MD.0000000000019453
_version_ 1783533213748035584
author Ding, Wei
Yang, Min
Jiang, Wanrong
Ge, Xiaolin
Sun, Xiangdong
Zhou, Bin
Liu, Feng
Jiang, Kai
Shen, Fangcheng
Sun, Xinchen
author_facet Ding, Wei
Yang, Min
Jiang, Wanrong
Ge, Xiaolin
Sun, Xiangdong
Zhou, Bin
Liu, Feng
Jiang, Kai
Shen, Fangcheng
Sun, Xinchen
author_sort Ding, Wei
collection PubMed
description This study aimed to retrospectively analyze the efficacy and safety of esophagectomy and postoperative radiotherapy (PORT) for patients with thoracic esophageal squamous cell carcinoma (TESCC) in the young–old (aged between 65 and 75 years). The clinical data of 166 young–old patients with esophageal cancer who underwent esophagectomy and PORT from May 2004 to May 2018 in The First Affiliated Hospital of Nanjing Medical University and The PLA Cancer Center, Jinling Hospital were analyzed. The Kaplan–Meier method was used to calculate overall survival (OS), disease-free survival (DFS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS). The log-rank method was used to test the differences. The Cox regression model was used for the multivariate prognostic analysis. The follow-up rate was 98.5%, and the median follow-up time was 41.2 months. The whole 1-, 3-, and 5-year OS rates were 92.0%, 69.3%, and 58.3%, respectively, and the median OS was 64.7 months (95% CI, 58.3–71.1). The median DFS was 57.9 months (95% CI, 47.4–68.4), and the 1-, 3-, and 5-year DFS rates were 84.8%, 61.5%, and 44.6%, respectively. The median LRFS was 60.8 months (95% CI, 50.5–71.0), and the 1-, 3-, and 5-year LRFS rates were 85.8%, 64.94%, and 53.9%, respectively. The median DMFS was 65.0 months (95% CI, 60.6–69.6), and the 1-, 3-, and 5-year DMFS rates were 91.9%, 77.0%, and 67.5%, respectively. Pathological T staging, lymph node metastasis, pathologic staging, and Karnofsk Performance Status (KPS) were the main factors affecting prognosis. In addition, T staging, lymph node metastasis are also independent prognostic factors. Little severe toxicity was observed. The result indicates that PORT for TESCC patients who can tolerate surgery is safe in the young–old. The efficacy is similar to that of previous patients including younger populations. Pathological T and N stage are major factors that affect prognosis. Concurrent chemotherapy may not improve the survival of the young–old patients undergoing postoperative radiotherapy.
format Online
Article
Text
id pubmed-7220665
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-72206652020-06-15 Postoperative radiotherapy for the young–old patients with thoracic esophageal squamous cell carcinoma: A 2-center experience Ding, Wei Yang, Min Jiang, Wanrong Ge, Xiaolin Sun, Xiangdong Zhou, Bin Liu, Feng Jiang, Kai Shen, Fangcheng Sun, Xinchen Medicine (Baltimore) 5700 This study aimed to retrospectively analyze the efficacy and safety of esophagectomy and postoperative radiotherapy (PORT) for patients with thoracic esophageal squamous cell carcinoma (TESCC) in the young–old (aged between 65 and 75 years). The clinical data of 166 young–old patients with esophageal cancer who underwent esophagectomy and PORT from May 2004 to May 2018 in The First Affiliated Hospital of Nanjing Medical University and The PLA Cancer Center, Jinling Hospital were analyzed. The Kaplan–Meier method was used to calculate overall survival (OS), disease-free survival (DFS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS). The log-rank method was used to test the differences. The Cox regression model was used for the multivariate prognostic analysis. The follow-up rate was 98.5%, and the median follow-up time was 41.2 months. The whole 1-, 3-, and 5-year OS rates were 92.0%, 69.3%, and 58.3%, respectively, and the median OS was 64.7 months (95% CI, 58.3–71.1). The median DFS was 57.9 months (95% CI, 47.4–68.4), and the 1-, 3-, and 5-year DFS rates were 84.8%, 61.5%, and 44.6%, respectively. The median LRFS was 60.8 months (95% CI, 50.5–71.0), and the 1-, 3-, and 5-year LRFS rates were 85.8%, 64.94%, and 53.9%, respectively. The median DMFS was 65.0 months (95% CI, 60.6–69.6), and the 1-, 3-, and 5-year DMFS rates were 91.9%, 77.0%, and 67.5%, respectively. Pathological T staging, lymph node metastasis, pathologic staging, and Karnofsk Performance Status (KPS) were the main factors affecting prognosis. In addition, T staging, lymph node metastasis are also independent prognostic factors. Little severe toxicity was observed. The result indicates that PORT for TESCC patients who can tolerate surgery is safe in the young–old. The efficacy is similar to that of previous patients including younger populations. Pathological T and N stage are major factors that affect prognosis. Concurrent chemotherapy may not improve the survival of the young–old patients undergoing postoperative radiotherapy. Wolters Kluwer Health 2020-04-24 /pmc/articles/PMC7220665/ /pubmed/32332598 http://dx.doi.org/10.1097/MD.0000000000019453 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 5700
Ding, Wei
Yang, Min
Jiang, Wanrong
Ge, Xiaolin
Sun, Xiangdong
Zhou, Bin
Liu, Feng
Jiang, Kai
Shen, Fangcheng
Sun, Xinchen
Postoperative radiotherapy for the young–old patients with thoracic esophageal squamous cell carcinoma: A 2-center experience
title Postoperative radiotherapy for the young–old patients with thoracic esophageal squamous cell carcinoma: A 2-center experience
title_full Postoperative radiotherapy for the young–old patients with thoracic esophageal squamous cell carcinoma: A 2-center experience
title_fullStr Postoperative radiotherapy for the young–old patients with thoracic esophageal squamous cell carcinoma: A 2-center experience
title_full_unstemmed Postoperative radiotherapy for the young–old patients with thoracic esophageal squamous cell carcinoma: A 2-center experience
title_short Postoperative radiotherapy for the young–old patients with thoracic esophageal squamous cell carcinoma: A 2-center experience
title_sort postoperative radiotherapy for the young–old patients with thoracic esophageal squamous cell carcinoma: a 2-center experience
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220665/
https://www.ncbi.nlm.nih.gov/pubmed/32332598
http://dx.doi.org/10.1097/MD.0000000000019453
work_keys_str_mv AT dingwei postoperativeradiotherapyfortheyoungoldpatientswiththoracicesophagealsquamouscellcarcinomaa2centerexperience
AT yangmin postoperativeradiotherapyfortheyoungoldpatientswiththoracicesophagealsquamouscellcarcinomaa2centerexperience
AT jiangwanrong postoperativeradiotherapyfortheyoungoldpatientswiththoracicesophagealsquamouscellcarcinomaa2centerexperience
AT gexiaolin postoperativeradiotherapyfortheyoungoldpatientswiththoracicesophagealsquamouscellcarcinomaa2centerexperience
AT sunxiangdong postoperativeradiotherapyfortheyoungoldpatientswiththoracicesophagealsquamouscellcarcinomaa2centerexperience
AT zhoubin postoperativeradiotherapyfortheyoungoldpatientswiththoracicesophagealsquamouscellcarcinomaa2centerexperience
AT liufeng postoperativeradiotherapyfortheyoungoldpatientswiththoracicesophagealsquamouscellcarcinomaa2centerexperience
AT jiangkai postoperativeradiotherapyfortheyoungoldpatientswiththoracicesophagealsquamouscellcarcinomaa2centerexperience
AT shenfangcheng postoperativeradiotherapyfortheyoungoldpatientswiththoracicesophagealsquamouscellcarcinomaa2centerexperience
AT sunxinchen postoperativeradiotherapyfortheyoungoldpatientswiththoracicesophagealsquamouscellcarcinomaa2centerexperience